title: Increased serum tumor necrosis factor α levels in patients with lenalidomide-induced hypothyroidism.
abstract: As the use of lenalidomide expands, the poorly understood phenomenon of lenalidomide-induced thyroid abnormalities will increase. In this study, we compared rates of therapy-induced hypothyroidism in 329 patients with diffuse large B-cell lymphoma (DLBCL) treated with conventional chemotherapy (DLBCL-c) or conventional chemotherapy plus lenalidomide (DLBCL-len). We measured serum levels of tumor necrosis factor α, interferon gamma, interleukin 6, interleukin 12, and interleukin 15 before and after treatment. We found a significantly higher rate of therapy-induced hypothyroidism in the DLBCL-len group (25.8% vs. 1.3%), and we found a statistically significant increase in serum tumor necrosis factor α in patients with lenalidomide-induced hypothyroidism.
authors.affiliation: Department of Internal Medicine, Vanderbilt University Medical Center, Nashville, TN, USA.
authors.forename: Wade T
authors.initials: WT
authors.lastname: Iams
authors.affiliation: Department of Pharmacology, Vanderbilt University Medical Center, Nashville, TN, USA.
authors.forename: Megan L
authors.initials: ML
authors.lastname: Hames
authors.affiliation: Division of Hematology/Oncology, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN, USA.
authors.forename: Judy P
authors.initials: JP
authors.lastname: Tsai
authors.affiliation: Department of Cancer Biology, Vanderbilt University Medical Center, Nashville, TN, USA.
authors.forename: Kimberly B
authors.initials: KB
authors.lastname: Dahlman
authors.affiliation: Department of Pharmacology, Vanderbilt University Medical Center, Nashville, TN, USA.
authors.forename: Mahsa S
authors.initials: MS
authors.lastname: Talbott
authors.affiliation: Division of Hematology/Oncology, Department of Medicine, University of North Carolina, Chapel Hill, NC, USA.
authors.forename: Kristy L
authors.initials: KL
authors.lastname: Richards
authors.affiliation: Division of Hematology/Oncology, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN, USA. Electronic address: nishitha.reddy@vanderbilt.edu.
authors.forename: Nishitha M
authors.initials: NM
authors.lastname: Reddy
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D058846:Antibodies, Monoclonal, Murine-Derived / Q000008:administration & dosage; D000970:Antineoplastic Agents / Q000008:administration & dosage; D000971:Antineoplastic Combined Chemotherapy Protocols; D005260:Female; D006801:Humans; D007037:Hypothyroidism / Q000097:blood / Q000139:chemically induced / Q000473:pathology*; D007155:Immunologic Factors / Q000009:adverse effects*; D007371:Interferon-gamma / Q000097:blood; D018664:Interleukin-12 / Q000097:blood; D019409:Interleukin-15 / Q000097:blood; D015850:Interleukin-6 / Q000097:blood; D000077269:Lenalidomide; D016403:Lymphoma, Large B-Cell, Diffuse / Q000097:blood / Q000188:drug therapy* / Q000473:pathology; D008297:Male; D008875:Middle Aged; D000069283:Rituximab; D012720:Severity of Illness Index; D013792:Thalidomide / Q000009:adverse effects / Q000031:analogs & derivatives*; D014409:Tumor Necrosis Factor-alpha / Q000097:blood*
chemical_list: D058846:Antibodies, Monoclonal, Murine-Derived; D000970:Antineoplastic Agents; C569274:IL15 protein, human; C508600:IL6 protein, human; D007155:Immunologic Factors; D019409:Interleukin-15; D015850:Interleukin-6; D014409:Tumor Necrosis Factor-alpha; D018664:Interleukin-12; D000069283:Rituximab; D013792:Thalidomide; D007371:Interferon-gamma; D000077269:Lenalidomide